Skip to main content
Immunovia logo

Immunovia — Investor Relations & Filings

Ticker · IMMNOV ISIN · SE0006091997 LEI · 549300KHWL6KK1XGUO81 ST Human health and social work activities
Open in API
Filings indexed 377 across all filing types
Latest filing 2022-04-14 Regulatory Filings
Country SE Sweden
Listing ST IMMNOV

About Immunovia

https://immunovia.com/

Immunovia is a diagnostics company focused on revolutionizing the early detection of pancreatic cancer. Its primary product is the PancreaSure test, a simple blood test designed to detect pancreatic cancer at Stage 1 and 2 with high accuracy. The test is intended for annual surveillance of individuals at elevated risk due to family history or genetic mutations. PancreaSure functions by detecting proteins and other biomarkers indicative of pancreatic cancer growth. The company's mission is to improve survival rates for this highly lethal cancer by enabling diagnosis at its earliest, most treatable stages, offering a convenient alternative to invasive imaging procedures.

Recent filings

Filing Released Lang Actions
Immunovia CPT PLA Code submission for the IMMray™ PanCan-d test is on the agenda of American Medical Association
Regulatory Filings Classification · 100% confidence The document is a press release dated April 14, 2022, announcing that Immunovia has submitted an application for a Current Procedural Terminology (CPT) Proprietary Laboratory Analyses (PLA) code to the American Medical Association (AMA) for its IMMray™ PanCan-d test. This announcement concerns a specific regulatory/procedural update related to medical coding and reimbursement in the US healthcare system. It is not a full financial report (10-K, IR), an earnings release (ER), a management discussion (MDA), or a standard investor presentation (IP). Since it details a specific procedural/regulatory step that impacts future claims processing, it fits best under the general 'Regulatory Filings' category (RNS) as a specific, non-financial regulatory update, or potentially 'LTR' if viewed as a regulatory process, but RNS is the most appropriate fallback for general regulatory announcements that don't fit the other specific codes. Given the nature of the announcement (a procedural update regarding a medical code submission), and the lack of a better fit among the specific financial/corporate action codes, RNS (Regulatory Filings) is the most suitable classification.
2022-04-14 English
Immunovias ansökan om CPT® PLA-kod för testet IMMray™ PanCan-d på agendan hos American Medical Association
Regulatory Filings Classification · 92% confidence The document is a press release dated April 14, 2022, announcing that Immunovia's US subsidiary has submitted an application for a CPT PLA code for their IMMray PanCan-d test to the American Medical Association (AMA). This announcement concerns a procedural/coding update related to a diagnostic test, which is a specific type of corporate or regulatory action. It is not a full financial report (10-K, IR), an earnings release (ER), a management discussion (MDA), or a dividend notice (DIV). Since it deals with regulatory/procedural updates concerning medical services coding in the US, and it doesn't fit neatly into the other specific categories like M&A (TAR) or Director's Dealing (DIRS), it falls best under the general 'Regulatory Filings' category (RNS) as a miscellaneous regulatory announcement, or potentially 'LTR' if viewed as a regulatory hurdle, but RNS is the most appropriate fallback for non-standard regulatory news. Given the context of AMA coding, it is a specific regulatory/procedural announcement, making RNS the best fit among the provided options for a non-financial, non-governance, non-legal-proceeding announcement.
2022-04-14 Swedish
Kommuniké från årsstämma i Immunovia AB
AGM Information Classification · 98% confidence The document is titled "Kommuniké från årsstämma i Immunovia AB" (Communiqué from the Annual General Meeting in Immunovia AB) and details the resolutions passed during the meeting held on April 7, 2022. Key decisions mentioned include the disposition of the company's loss, approval of remuneration, election/re-election of board members and auditors, approval of the remuneration report, authorization for new share issues, and decisions regarding incentive programs. These topics are central to an Annual General Meeting (AGM). Although it summarizes the outcomes, it is not the formal voting result announcement (DVA) nor the full proxy material (PSI). It functions as the official summary/release of the AGM proceedings. Therefore, the most appropriate classification is AGM Information (AGM-R).
2022-04-07 Swedish
Communiqué from the Annual General Meeting in Immunovia AB
AGM Information Classification · 99% confidence The document is explicitly titled 'Communiqué from the Annual General Meeting in Immunovia AB' and details the resolutions passed during the meeting held on April 7, 2022. Key topics covered include profit allocation, discharge from liability, board member elections, remuneration, and authorizations for share issues. These contents are characteristic of the formal documentation summarizing the outcomes of an Annual General Meeting (AGM). Therefore, the appropriate classification is AGM-R.
2022-04-07 English
Immunovia utser Jeff Borcherding, tidigare marknadschef på Myriad Genetics, till att leda Immunovias USA-verksamhet
Board/Management Information Classification · 100% confidence The document is a press release ("PRESSMEDDELANDE") dated March 28, 2022, announcing the appointment of Jeff Borcherding as the CEO of Immunovia's US subsidiary. This announcement concerns a change in senior management/board structure. According to the definitions, the category for 'Announcement of changes in the company's board of directors or senior management' is Board/Management Information (MANG). The document is short and clearly an announcement, not a comprehensive report.
2022-03-28 Swedish
Immunovia appoints Jeff Borcherding, previously Chief Marketing Officer at Myriad Genetics, to lead Immunovia’s US business
Board/Management Information Classification · 100% confidence The document is a press release announcing the appointment of a new CEO for the US subsidiary, Jeff Borcherding. This type of announcement concerns changes in senior management personnel. Based on the provided definitions, the category 'Board/Management Information (Code: MANG)' is the most appropriate fit, as it covers 'Announcement of changes in the company's board of directors or senior management.' The document is not a formal regulatory filing like a 10-K, an earnings release, or a dividend notice, but a specific corporate personnel update.
2022-03-28 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.